

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | IMARADENANT |
| INN | imaradenant |
| Description | Imaradenant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target adenosine receptor A2b, adenosine receptor A1, and adenosine receptor A2a. |
| Classification | Small molecule |
| Drug class | adenosine receptor antagonists |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(-c2nnc(N)nc2-c2ccc(F)cc2)cc(Cl)n1 |
| PDB | — |
| CAS-ID | 1321514-06-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594442 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 770140J08A (ChemIDplus, GSRS) |
